The key benchmark indices traded with moderate gains in morning trade, supported by buying interest amid positive global ...

Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses.

Notably, the companys EBITDA surged by 16.5 percent, increasing from Rs 586.3 crore to Rs 683.2 crore from previous year. However, the profit margins stood at 22.2 percent, a slight decrease from the ...

The company’s strategy for global markets is different from the India market and is not solely based on leveraging ...

The pharmaceutical company is evaluating all options to increase its presence in therapy areas, including in-licensing ...

Ahead of Mankind Pharma's listing, global brokerage Macquarie initiated coverage on the stock with an outperform rating and a target price of Rs 1,400 apiece, based on 25 times FY25e PER ...

Shares of Mankind Pharma slipped 4 percent to Rs 2,606, snapping its two-day gaining streak on the bourses on January 21 after Macquarie downgraded Mankind Pharma to "Underperform" with a target ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn ...

July 25 (Reuters) - Indian drugmaker Mankind Pharma (MNKI.NS), opens new tab said late on Thursday it would acquire Bharat Serums and Vaccines Ltd in a deal valued at around 136.30 billion rupees ...

New Delhi: A consortium of Warburg Pincus and ChrysCapital will compete with TPG, Blackstone and EQT, as well as Mankind Pharma, to acquire BSV Group, formerly Bharat Serum & Vaccines Ltd ...